Named patient and other compassionate use schemes in Europe: far from a single market
This article was originally published in SRA
Executive Summary
Mats Ericson and Catherine Akers* together with other members of the EBE biopharmaceutical industry grouping compiled a comparative overview of the named patient and other compassionate use programmes that are available in Europe. They report here on the multitude of schemes that are available.